Anne‐Marie Duliège

2.9k total citations · 1 hit paper
51 papers, 1.9k citations indexed

About

Anne‐Marie Duliège is a scholar working on Hematology, Virology and Epidemiology. According to data from OpenAlex, Anne‐Marie Duliège has authored 51 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 17 papers in Virology and 11 papers in Epidemiology. Recurrent topics in Anne‐Marie Duliège's work include HIV Research and Treatment (17 papers), Erythropoietin and Anemia Treatment (13 papers) and HIV/AIDS Research and Interventions (7 papers). Anne‐Marie Duliège is often cited by papers focused on HIV Research and Treatment (17 papers), Erythropoietin and Anemia Treatment (13 papers) and HIV/AIDS Research and Interventions (7 papers). Anne‐Marie Duliège collaborates with scholars based in United States, United Kingdom and Canada. Anne‐Marie Duliège's co-authors include Jean‐Louis Excler, Rae Lyn Burke, Rose E. Sekulovich, Robert F. Pass, Sandra Percell, Kent J. Weinhold, Suresh B. Boppana, William J. Britt, Hany Zayed and James B. Bussel and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Anne‐Marie Duliège

51 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

2018 237 citations James B. Bussel, Donald M. Arnold et al. American Journal of Hematology profile →

Peers

Countries citing papers authored by Anne‐Marie Duliège

Since Specialization

Citations

This map shows the geographic impact of Anne‐Marie Duliège's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne‐Marie Duliège with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne‐Marie Duliège more than expected).

Fields of papers citing papers by Anne‐Marie Duliège

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne‐Marie Duliège. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne‐Marie Duliège. The network helps show where Anne‐Marie Duliège may publish in the future.

Co-authorship network of co-authors of Anne‐Marie Duliège

This figure shows the co-authorship network connecting the top 25 collaborators of Anne‐Marie Duliège. A scholar is included among the top collaborators of Anne‐Marie Duliège based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne‐Marie Duliège. Anne‐Marie Duliège is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials breakdown → 2018 ·American Journal of Hematology ·James B. Bussel, Donald M. Arnold, (unknown), Jiřı́ Mayer, Jacek Treliński, Wojciech Homenda, Andrzej Hellmann, Jerzy Windyga, Liliya Sivcheva, Alhossain A. Khalafallah, Francesco Zaja, Nichola Cooper, Vadim Markovtsov, Hany Zayed, Anne‐Marie Duliège	237
2	Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program 2018 ·Blood ·Anne‐Marie Duliège, Donald M. Arnold, Ralph V. Boccia, Michael Boxer, Nichola Cooper, Quentin A. Hill, Darla Liles, Michelle Sholzberg, Hany Zayed, Sandra Tong, James B. Bussel	8
3	Long-Term Maintenance of Platelet Responses in Adult Patients with Persistent/Chronic Immune Thrombocytopenia Treated with Fostamatinib: 1-Year Efficacy and Safety Results 2017 ·Blood ·James B. Bussel, Donald M. Arnold, Nichola Cooper, Alhossain A. Khalafallah, Michael Boxer, Darla Liles, Waleed Ghanima, Keith R. McCrae, Hany Zayed, Benoît Cadieux, Anne‐Marie Duliège	2
4	Peginesatide in Patients with Anemia Undergoing Hemodialysis 2013 ·New England Journal of Medicine ·Steven Fishbane, Brigitte Schiller, Francesco Locatelli, Adrian Covic, Robert Provenzano, Andrzej Więcek, Nathan W. Levin, Mark Kaplan, Iain C. Macdougall, (unknown), Martha Mayo, Krishna R. Polu, Anne‐Marie Duliège, Anatole Besarab	69
5	Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis 2013 ·New England Journal of Medicine ·Iain C. Macdougall, Robert Provenzano, Amit Sharma, Bruce Spinowitz, Rebecca J. Schmidt, Pablo E. Pérgola, Raja I. Zabaneh, Sandra Tong-Starksen, Martha Mayo, Hong Tang, Krishna R. Polu, Anne‐Marie Duliège, Steven Fishbane	78
6	Dose-finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients 2011 ·Clinical Journal of the American Society of Nephrology ·Iain C. Macdougall, Andrzej Więcek, Beatriz Tucker, Magdi Yaqoob, Ashraf Mikhail, Michał Nowicki, Iain MacPhee, M Myśliwiec, (unknown), Władysław Sułowicz, Martha Mayo, (unknown), Krishna R. Polu, Peter J. Schatz, Anne‐Marie Duliège	18
7	A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia 2009 ·New England Journal of Medicine ·Iain C. Macdougall, Jérôme Rossert, Nicole Casadevall, Richard B. Stead, Anne‐Marie Duliège, Marc Froissart, Kai‐Uwe Eckardt	95
8	Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers 2007 ·The Journal of Clinical Pharmacology ·Sukyung Woo, Wojciech Krzyżański, Anne‐Marie Duliège, (unknown), (unknown)	22
9	Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers 2006 ·Blood ·Richard B. Stead, John S. Lambert, (unknown), Julie Iwashita, Kerstin K. Leuther, Kathryn W. Woodburn, Peter J. Schatz, (unknown), Robert Naso, Anne‐Marie Duliège	88
10	Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1 2003 ·AIDS Research and Human Retroviruses ·Jérôme H. Kim, Punnee Pitisuttithum, (unknown), Thippawan Chuenchitra, John R. Mascola, Sarah S. Frankel, Mark S. deSouza, Victoria R. Polonis, Robert McLinden, Anna Sambor, Arthur E. Brown, Benjaluck Phonrat, Kittipong Rungruengthanakit, Anne‐Marie Duliège, Merlin L. Robb, John J. McNeil, Deborah L. Birx	19
11	Safety and Immunogenicity of Combinations of Recombinant Subtype E and B Human Immunodeficiency Virus Type 1 Envelope Glycoprotein 120 Vaccines in Healthy Thai Adults 2003 ·The Journal of Infectious Diseases ·Punnee Pitisuttithum, Sorachai Nitayaphan, P Thongcharoen, Chirasak Khamboonruang, Jérôme H. Kim, Mark de Souza, Thippawan Chuenchitra, Robin P. Garner, Darawan Thapinta, Victoria R. Polonis, Silvia Ratto‐Kim, Penprapa Chanbancherd, Joseph Chiu, Deborah L. Birx, Anne‐Marie Duliège, John G. McNeil, Arthur E. Brown, (unknown)	51
12	Safety of 2 Recombinant Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Vaccines in Neonates Born to HIV-1-Infected Women 2001 ·Clinical Infectious Diseases ·Coleen K. Cunningham, D. W. Wara, Minhee Kang, Terry Fenton, Elizabeth Hawkins, James McNamara, Lynne Mofenson, Anne‐Marie Duliège, (unknown), Elizabeth J. McFarland, William Borkowsky	58
13	Antibodies to the Major Linear Neutralizing Domains of Cytomegalovirus Glycoprotein B Among Natural Seropositives and CMV Subunit Vaccine Recipients 2000 ·Viral Immunology ·Gary S. Marshall, Mengtao Li, (unknown), (unknown), Anne‐Marie Duliège, Rae Lyn Burke, (unknown)	19
14	A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais 2000 ·Vaccine ·Sorachai Nitayaphan, Chirasak Khamboonruang, (unknown), Patricia Morgan, Joseph Chiu, Anne‐Marie Duliège, (unknown), (unknown), Kittipong Rungruengthanakit, Mark S. deSouza, John R. Mascola, (unknown), Silvia Ratto‐Kim, Lauri E. Markowitz, Deborah L. Birx, Vinai Suriyanon, John G. McNeil, Arthur E. Brown, (unknown)	48
15	A Subunit Cytomegalovirus Vaccine Based on Recombinant Envelope Glycoprotein B and a New Adjuvant 1999 ·The Journal of Infectious Diseases ·Robert F. Pass, Anne‐Marie Duliège, Suresh B. Boppana, Rose E. Sekulovich, Sandra Percell, William J. Britt, Rae Lyn Burke	196
16	Effects of Antigen Dose and Immunization Regimens on Antibody Responses to a Cytomegalovirus Glycoprotein B Subunit Vaccine 1999 ·The Journal of Infectious Diseases ·Sharon E. Frey, Christopher Harrison, Robert F. Pass, (unknown), Daniel J. Boken, Rose E. Sekulovich, Sandra Percell, Allen Izu, Sue E. Hirabayashi, Rae Lyn Burke, Anne‐Marie Duliège	86
17	Neutralization of Syncytium‐Inducing Primary Isolates by Sera from Human Immunodeficiency Virus (HIV)–Uninfected Recipients of Candidate HIV Vaccines 1998 ·The Journal of Infectious Diseases ·Susan Zolla‐Pazner, Serena Xu, Sherri Burda, Anne‐Marie Duliège, Jean‐Louis Excler, Mary Lou Clements‐Mann	13
18	Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers 1998 ·AIDS ·Robert B. Belshe, Geoffrey J. Gorse, Mark J. Mulligan, Thomas G. Evans, Michael C. Keefer, Jean‐Louis Excler, Anne‐Marie Duliège, James Tartaglia, William I. Cox, James McNamara, Kai-Lin Hwang, (unknown), David C. Montefiori, Kent J. Weinhold	140
19	Neutralization of a Clade B Primary Isolate by Sera from Human Immunodeficiency Virus—Uninfected Recipients of Candidate AIDS Vaccines 1997 ·The Journal of Infectious Diseases ·Susan Zolla‐Pazner, Carl R. Alving, Robert B. Belshe, Phillip W. Berman, Sherri Burda, (unknown), M L Clements, Anne‐Marie Duliège, Jean‐Louis Excler, Catarina E. Hioe, James O. Kahn, M. Juliana McElrath, Sandra Sharpe, Faruk Sinangil, Kathelyn S. Steimer, Mary Clare Walker, Nabila M. Wassef, Serena Xu	39
20	Clinical, Immunologic, and Virologic Observations Related to Human Immunodeficiency Virus (HIV) Type 1 Infection in a Volunteer in an HIV-1 Vaccine Clinical Trial 1995 ·The Journal of Infectious Diseases ·James O. Kahn, Kathelyn S. Steimer, Jürg Baenziger, Anne‐Marie Duliège, Mark B. Feinberg, Tarek Elbeik, Margaret A. Chesney, (unknown), David Chernoff, Faruk Sinangil	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact